Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,601–14,700 of 15,747
Hayany, B. E., Alahyane, A., & Lafhal, K. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-6730-8.ch012
Yang, X., Sang, R., Hutvágner, G., Hewitt, A. W., Li, D., Li, Y., & Deng, W. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.05.044 · Cited by 1
Investigation of neutralizing antibody titers after mRNA SARS‒CoV‒2 vaccination in dialysis patients
Suzuki, K., Hitomi, T., Suzuki, S., & Yamaoka, M. (2022) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.55.53
Koronavaksinering av kreftpasienter
Brustugun, O. T., & Heggelund, L. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0026
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Vorontsov, O. M., Zigron, R., Kleinstern, G., Wolf, D. G., & Porat, S. (2021) · medRxiv · doi:10.1101/2021.08.30.21262875
Molecular concepts for pandemic viruses : membrane fusion assays and targeting of reservoir cells
Theuerkauf, S. A. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.86442
The Importance of Qualitative/Quantitative Analytical Tools in COVID-19 Vaccine Development
Seyfinejad, B., Molavi, O., & Jouyban, A. (2023) · ImmunoAnalysis · doi:10.34172/ia.2023.08
Insights into the T-cell response to SARS-CoV-2
Kadi, C., Najimi, N., Zakaria, M., Bakri, Y., Noureddine, E., & Fouad, S. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231211458
SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 – June 30, 2021
Darby, B. J., Alexander, V., & Murphy, J. M. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.041
Muminov, M., Tsiferova, N. A., Pshenichnov, E., Ermatova, K., Charishnikova, O. S., Abdullaev, A. A., Levitskaya, Y., Akbarovna, D. D., Sandhya, M. V. S., Tomar, G. B., et al. (2024) · Vaccines · doi:10.3390/vaccines12121420
Impact of Vaccination on the COVID-19 Pandemic: Evidence from U.S. StatesPreprint
Chen, X., Huang, H., Ju, J., Sun, R., & Zhang, J. (2021) · Research Square · doi:10.21203/rs.3.rs-636588/v1
Ding, K., Naqvi, O. H., Seeberger, R. J., Bratzler, D. W., & Wendelboe, A. M. (2024) · Emerging infectious diseases · doi:10.3201/eid3011.231582
Fairlamb, M. S., Kumru, O. S., Hickey, J. M., et al. (2025) · doi:10.12688/verixiv.1767.1
Arepalli, S., Kopplin, L. J., Tsui, E. Y. K., Brill, D. A., Sobrin, L., Papaliodis, G. N., Darwish, D., Raiji, V. R., Janardhana, P., Emami-Naeini, P., et al. (2025) · Retina · doi:10.1097/iae.0000000000004413 · Cited by 3
Healy, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-54841-0.00006-8
Mise‐Omata, S., Ikeda, M., Takeshita, M., Uwamino, Y., Wakui, M., Arai, T., Yoshifuji, A., Murano, K., Siomi, H., Nakagawara, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.31.500554
“3% currently, and severe cases have been greatly reduced (1, 2).”
BackgroundFigueroa, E. B., Vazquez‐Benitez, G., Ehresmann, K., Seburg, E. M., Daida, Y. G., Vesco, K. K., Sidebottom, A., Lipkind, H. S., DeSilva, M. B., Cao, J., et al. (2026) · American Journal of Epidemiology · doi:10.1093/aje/kwag105 · Cited by 1
Hayashi, R., Takami, Y., Fujigaki, H., Amano, K., Akita, K., Yamana, K., Maekawa, A., Saito, K., & Takagi, Y. (2024) · The International Journal of Artificial Organs · doi:10.1177/03913988241234475
El mundo necesita ciencia de calidad más que nunca
Ferreira‐Hermosillo, A. (2021) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m20000006
Infectious, Immune-Mediated, and Vaccine-Associated Ocular Adverse Events
Rojas, R., & Hinkle, D. M. (2025) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683251363420
Kassani, A., Khosropanah, A., Mard‐Soltani, M., Dolatshahi, M., & Mohebbi, L. (2024) · Journal of Advanced Immunopharmacology · doi:10.5812/jai-163705
The Variance-Stabilizing Transformation for the Poisson Rate Ratio: Closed-Form Confidence IntervalsPreprint
Ng, S.-P. (2026) · medRxiv · doi:10.64898/2026.07.16.26358255
Tsai, W. H., & Liaw, Y. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14602
Bell’s Palsy Following SARS-CoV-2 Vaccines: A Systematic Review and Meta-AnalysisPreprint
Rafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2022) · medRxiv · doi:10.1101/2022.10.26.22281537
“Of the excluded studies, three records (42-44) were the reports of preliminary results of the”
BackgroundIntramuscular administration of LNP-mRNA therapeutics
Tanzadehpanah, H., Mahaki, H., Sheykhasan, M., Alavi-Kakhki, S. S., Sardou, H. S., Mobarezi, Z., Esfandiari, A. H., Meshkat, Z., Afkhami, H., & Manoochehri, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00015-x
Huguet, M., Boigués, M., Sorigué, M., Blanco, J., Quirant‐Sánchez, B., Ferra, C. M., Huguet, M., Boigués, M., Morgades, M., Felip, E., et al. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.03.002
Golemi‐Kotra, D., & Wu, J. (2021) · doi:10.64628/aam.tgwps3qh9
Marconato, M., Jäger, S., Tegeler, C. M., Hackenbruch, C., Salih, H. R., Walz, J. S., Federmann, B., & Heitmann, J. S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1844041
Liu, C.-W., Jeyakumar, N., McArthur, E., Sontrop, J. M., Myran, D. T., Schwartz, K. L., Sood, M. M., Tanuseputro, P., & Garg, A. X. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080461 · Cited by 1
Puzek, B., Wratil, P. R., Janke, C., Thi, T. G. L., Rubio‐Acero, R., Lupoli, G., Schoof, I. C., Stern, M., Zhelyazkova, A., Rech, J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117981
Louten, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90565-7.00014-9
Parisi, G., Renault, V., Humblet, M., Ochelen, N., Diep, A., Guillaume, M., Donneau, A., Bureau, F., Gillet, L., Lange, A.-C., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811523
“By that time, vaccines had demonstrated their ability to reduce the number of cases of COVID-19 [5,6] but little was known about their ability to reduce the virus transmission once a person was infected.”
BackgroundEstimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials
(2022) · doi:10.1101/2022.02.02.22270317
“In addition, these trials consider different populations, vaccine efficacy estimators and disagree in the way intercurrent events are handled [1, 24, 28, 32].”
BackgroundMethodExamination of the Dead Volume in Different COVID-19 Vaccine Tozinameran Delivery Systems
Watanabe, T., INABA, Y., SHIMBO, H., et al. (2021) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.95.381
Fuentes-Garay, G. A., Arteaga-Carrillo, S. H., Fuentes-Muñoz, N. R., & Hernández-Castro, C. A. (2026) · Enfermería Universitaria · doi:10.22201/feno.23958421e.2023.2.1507
The Rationale Behind the Effectiveness of COVID-19 Vaccines and Associated Immunological Mechanisms
Khatib, S. E. (2022) · Turkish Journal of Immunology · doi:10.4274/tji.galenos.2022.55264
(2023) · doi:10.1101/2023.06.22.23291692
“The first emergency use authorization (EUA) of vaccines for Coronavirus Disease 2019 (COVID-19) in the US in December 2020 ushered in a new era of the pandemic, with mRNA vaccines having shown strong efficacy against both confirmed infection and severe outcomes in randomized clinical trials.(1) After the EUA and broad…”
BackgroundAcute pancreatitis occurring after COVID-19 vaccine: a case report and literature review
Kabaoglu, C., Özışık, H., Kocabaş, G. Ü., et al. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00362-0
“The Pfizer-BioNTech COVID-19 vaccine, based on mRNA technology targeting the SARS-CoV-2 spike protein, has known systemic and local adverse effects [2].”
BackgroundKarim, Q. A., Baum, F. E., & Detels, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198816805.002.0013
Bazarjav, P., Erdene-Ochir, T., Sandagdorj, A., Enkhtuvshin, A., Enkhbayar, P., Ganbold, S., Baatarsuren, N., Oyun-Erdene, S., Batmunkh, B., Jantsansengee, B., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129179
SARS-CoV-2 spike protein in infectivity
Altaie, A. M., Hamdy, R., Husseiny, M. I., & Soliman, S. S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00015-2
Retrospective Analysis of Equity-Based Optimization for COVID-19 Vaccine AllocationPreprint
Stafford, E., Dimitrov, D., Ceballos, R. M., et al. (2023) · medRxiv · doi:10.1101/2023.05.08.23289679
CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination
Pan, Y., Hofmann, C., Banbury, B. L., Patel, H., Bien, S. A., Chou, T., & Yang, O. O. (2026) · Journal of Immunological Methods · doi:10.1016/j.jim.2026.114088
Nueva era de las vacunas: nuevas interrogantes
Alfaro, C. O. (2020) · REVISTA PERUANA DE CIENCIAS DE LA SALUD · doi:10.37711/rpcs.2020.2.4.223
“Booster Vaccine” to Mitigate the Threat of “Emerging COVID-19 Variants”: A short Review
Pandian, M., Veepanattu, P., Moni, M., & Sathyapalan, D. T. (2021) · Amrita Journal of Medicine · doi:10.4103/amjm.amjm_5_22
Manesh, A., Muliyil, D. E., Singh, B., Oommen, A. M., Chowdhury, S. D., & Brett‐Major, D. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-7959-7.00028-2
Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta DominancePreprint
Islam, N., Griffin, D. O., Jarvis, M. S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4145598
Expertise scientifique, débat public et décisions de sécurité sanitaire
Oualikene-Gonin, W., Castel, P., Paccaud, F., Maison, P., & Ankri, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.10.014 · Cited by 1
Erskine, F. S. M., Spensley, K. J., Prendecki, M. F., Santos, E., Anand, A., Altmann, D. M., & Willicombe, M. K. (2025) · HLA · doi:10.1111/tan.70076
Imagination and idealism after the COVID-19 pandemic: the science of healthy ageing
Farrelly, C. (2024) · Royal Society Open Science · doi:10.1098/rsos.231102
Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy–Treated People With HIV
Mitha, E., Berhe, M., Aberg, J. A., LUCASTI, C. J., Chalhoub, F., Kitchin, N. R. E., Vogler, I., Lockhart, S. P., Fuchs, S., Quandt, J., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag310
“…reactions up to 7 days post–dose 1 and dose 2 were comparable to those reported by the HIV-negative cohort (Supplementary Figures 1 and 2), and frequencies of AEs re-ported by PWH were comparable to those previously published in the wider HIV-negative population (Supplementary Table 5) [6, 15].”
InfluentialSelf-citationPotential socioeconomic approaches for commercialized antimicrobial applications
Jangra, P., Negi, G., Sharma, A., & Parveen, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99148-3.00008-x
Sellars, S. (2021) · BDJ · doi:10.1038/s41415-021-3777-2
A Survey Based Analysis to Study the Side Effects of Covid-19 Vaccination in Punjab (India)
Juneja, N., Grover, A., Kaur, H., & Sheetal, A. (2023) · Wireless Personal Communications · doi:10.1007/s11277-023-10665-0
“Owing to the adverse effects of these above mentioned vaccines, they have been rolled out across the UK respectively on 8th December, 2020, and 4th January, 2021 [5, 8].”
Le, D. T. H., Yang, C., Zhang, Y., Zhao, G., Seow, B. Y. L., Zhao, X., Balakrishnan, N., Bae, K. H., Hui, J. H. P., & Yang, Y. Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115136
Majumder, N., & Arefin, M. R. (2026) · Royal Society Open Science · doi:10.1098/rsos.252509
Historical Development Process of mRNA Vaccines and SARS-CoV-2 Pandemic
GÜNEŞ, N., & Karabulut, Ş. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.14
Cost‐Effectiveness of Vaccination Strategies for COVID‐19: A Systematic Review
Yang, Y., Weng, J., Tao, Y., Luo, B., Lian, D., Li, F., Yan, J., & Chen, Y. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70136
“While COVID-19 vaccines are established as safe and effective tools for pandemic management, the continuous emergence of variants and shifting booster policies necessitate an updated evidence synthesis to inform resource allocation [ 74–77 ].”
Coronavirus Disease 2019 Vaccines and Pregnancy: Present and Future
Pae, J., & Ko, H. S. (2021) · Perinatology · doi:10.14734/pn.2021.32.3.111
Hong, T., Masuda, K., Nakashima, Y., Li, S., Chen, P., Hu, G., Igarashi, K., Kimura, A., Fujita, K., Umezu, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114274 · Cited by 2
(2021) · doi:10.1101/2021.09.08.21263248
“56 While the role of cellular immunity is yet to be fully elucidated (14), several studies 57 suggest that the efficacy of currently approved COVID-19 vaccines is attributable to the 58 neutralizing antibodies they elicit (6, 11, 15-20).”
BackgroundSchulte, M., Leithäuser, N., & Mohring, J. (2026) · BMC Public Health · doi:10.1186/s12889-026-27264-w · Cited by 1
Tiroidite subacuta e vaccino anti SARS-CoV-2
Colapinto, A., Pagotto, U., & Repaci, A. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01441-8
Harnessing mRNA to unleash endolysins: A new frontier in antibacterial therapy
Nelson, D. C., Dave, U. M., & González-Juarbe, N. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102249
Lukaschek, K., Hofbauer, S., Dreischulte, T., Drey, M., Rottenkolber, M., Winter, S., Sebastião, M., Teupser, D., Gágyor, I., Hausen, A., et al. (2026) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000551288
Commentary on “Risk of venous thromboembolism after COVID‐19 vaccination”
Frère, C., & Salem, J. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15735
Miyamoto, N., Yamaguchi, T., Tamada, Y., Yamayoshi, S., Murashita, K., Itoh, K., Imoto, S., Saito, N., Mikami, T., & Nakaji, S. (2026) · Vaccines · doi:10.3390/vaccines14020115
“In Japan, the COVID-19 vaccines Comirnaty from Pfizer Inc. [10], Spikevax from Moderna Inc. [11], and Vaxzevria from AstraZeneca PLC [12] were approved as medical drugs since 2021.”
Araki, K., Shimizu, N., Iijima, M., et al. (2022) · Reports — Medical Cases Images and Videos · doi:10.3390/reports5040048
“The BNT162b2 vaccine consists of mRNA encased in a lipid membrane [3].”
BackgroundHong, A., & Sardinas, G. (2022) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1452
[Antithrombotic prophylaxis of the complications of arteriosclerosis obliterans].
Heine, H., Norden, K., Heinemann, L., Stepanauskas, M., & Schmidt, H. (1981) · PubMed
Goel, M., Gupta, K., Srivastava, I., & Gabrani, R. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80189-1_15
La vacunación contra COVID-19. Desarrollo y perspectivas
Cabrera, J. L., & Benavides, A. G. (2023) · Interciencia médica · doi:10.56838/icmed.v13i2.141
Effect of Homologous and Heterologous Booster in COVID-19 Vaccination
Vukčević, M., Despot, M., Nikolić‐Kokić, A., Blagojević, D. P., Nikolic, M. R., Banko, A. V., Jovanović, T., & Despot, D. (2024) · Pharmaceuticals · doi:10.3390/ph17121734
“The rapid Pharmaceuticals 2024 , 17 , 1734 2 of 15 development of vaccines has been the most important key to successfully controlling the pandemic [6].”
Conformational variability of loops in the SARS-CoV-2 spike proteinPreprint
Wong, S. W. K., & Liu, Z. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2105.08835
Public Health Must Transcend Folkbiology
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0006
Ri, Y., Oshima, S., Tanaka, H., Sugawara, T., Hori, M., Siril, Y. J., Nakai, Y., Ito, K., Shimoya, K., Sakurai, Y., et al. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c00925
Acceptance of the COVID-19 Vaccine Among Postpartum Women in Five Countries
Lee, E. Y., Chien, L.-Y., Chang, Y.-S., Hong, S. A., & Coca, K. P. (2025) · Women s Health Reports · doi:10.1089/whr.2024.0202 · Cited by 1
Kasamatsu, T., Kajita, A., HATAKEYAMA, K., & Kenji, U. N. O. (2022) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.96.56
Seow, J., Graham, C., Hallett, S. R., Lechmere, T., Maguire, T., Huettner, I., Cox, D., Roberts, R., Waters, A., Ward, C. C., et al. (2021) · bioRxiv · doi:10.1101/2021.09.27.461862
Pokhrel, B., Bijukchhe, S. M., O'Reilly, P., Gurung, M., Rockett, R. J., Golubchik, T., Zhang, Y., Kelly, S. C., Basi, R., Curtis, B., et al. (2026) · Vaccine X · doi:10.1016/j.jvacx.2026.100864
Şahinci, M. N., Döşkaya, M., Karakavuk, M., Kaplan, S., Mutlu, G., Perçin, T. G., Alak, S. E., Günay-Esiyok, Ö., Gül, A., Döşkaya, A. D., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149965 · Cited by 1
Miran, C., Bonnet, É., Allignet, B., et al. (2021) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2021.03.005
Tracking the Trail of Monkeypox: From Origins to Outbreak Control
Jangir, A., Swami, A., Kumari, N. P., Kumar, H., Arya, H., Yadav, N., Kumar, D., & Bhatt, T. K. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70239 · Cited by 1
Rubin, E. J. (2025) · New England Journal of Medicine · doi:10.1056/nejme2513817
(2022) · doi:10.1101/2022.04.15.22273412
“COVID-19 vaccines approved or authorized for emergency use in the US by the Food and Drug 24 Administration had high efficacy against severe disease in Phase III trials, ranging from 67% to 95% [1, 3-5].”
BackgroundUltrasound-assisted antifouling for continuous microfluidic manufacturing of RNA–LNP
Hwang, Y., Kim, G., Dinh, H., et al. (2026) · Lab on a Chip · doi:10.1039/d6lc00340k
REGEN-COV as the First Line of Defense—A Single-Centre Experience
Popović, M., Đurović, V., Ljubičić, B., Kovačević, N., Sajinovic, S., Petrović, L., Ilić, T., & Golubović, S. (2026) · Life · doi:10.3390/life16010074
Pediatric Covid Vaccination: A Jab in Time Could Save Little Ones in their Prime!
Gopan, A. (2022) · Annals of Pediatric Gastroenterology & Hepatology · doi:10.5005/jp-journals-11009-0084
Schlaiß, T. N., Vassilenko, M. D., Kimmel, T., Diessner, J., Wöckel, A., McNeill, R. V., Kittel‐Schneider, S., Kämmerer, U., & Bartmann, C. (2025) · Oncology Research and Treatment · doi:10.1159/000546837
COVID-19 vaccine-elicited immune mediators and their contribution to protective immunity
Mishra, A., Mallik, S., Chatterjee, S., Naser, S. M., & Mukhopadhyay, S. (2026) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20260725
Augmenting the Cytotoxicity of Anticancer Peptide K6L9 by In Vitro-Synthesized mRNA
Njoka, M., Covarrubias‐Zambrano, O., Tripathi, A., Santana-Magal, N., Jeppson, J. D., Akhavan, D., Pyaram, K., Bossmann, S. H., & Kamath, D. V. (2026) · Applied Sciences · doi:10.3390/app16073288 · Cited by 1
A Novel CRISPR-Engineered, Stem Cell-Derived Cellular VaccinePreprint
Chakraborty, K., Chandrashekar, A., Sidaway, A., Latta, E., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., Mosher, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.28.474336
Gatenby, W., Dominah, G. A., Paudel, A., et al. (2022) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1107
COVID-19 Vaccine: Concerns and Comfort, Who Should Take It?
Mohammad, K. (2021) · doi:10.36959/669/746
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.